Searching for Early Detection Biomarkers and to Reduce Mortality Rate of Hepatocellular Cancer (HCC) in Zhongshan City
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20,000
- 试验地点
- 1
- 主要终点
- 5-year HCC specific mortality rate
研究概览
简要总结
All participants in the selected communities will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be performed. High risk group will be selected according to the definition. HCC diagnosis will be determined according to imaging and/or biopsy result. Repeated check-ups will be performed in 6-months among HBsAg positive group and 3-years among HBsAg negative group.
All subjects in the control arm (control communities) will be followed by record linkage to Cancer Register and Population Register.
详细描述
Sample selection
- Select communities of 70,000 to 120,000 populations in Zhongshan City as the investigators' fields.
- Divide them into screening group and control group according to the areas of administration
Participants recruitment
- Subjects voluntarily attend this screening study
Informed consent - Informed consent forms will be collected at the recruitment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 35 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Residences in Zhongshan City
- •Have no medical records of hepatocellular cancer
- •Provide written informed consent forms
- •Have a good physical and psychological condition
排除标准
- •Have severe cardiovascular or kidney disease
- •Have medical records of hepatocellular cancer
结局指标
主要结局
5-year HCC specific mortality rate
时间窗: 10 years
To reduce 5-year HCC specific mortality rate compare with that of general population
次要结局
- Early diagnosis rate of HCC(5 years)
- Identification of early diagnosis markers of HCC(5 years)
研究者
Mingfang Ji
Dr. Mingfang Ji
Zhongshan People's Hospital, Guangdong, China